Company
Hummingbird Bioscience
A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company.
At a glance
- Listing
- Private, not listed
- Category
- Pharma
- Headquarters
- The Galen, 61 Science Park Road, #06-15, Singapore 117525
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Pharma
- Market
- Singapore
- Recent inflection
- 6 January 2026: first patient dosed in the Phase I clinical trial of HMBD-501 in patients with advanced HER3-expressing solid malignancies (company news page, hummingbirdbioscience.com/news).
- Services
- None recorded
- People tracked
- 2
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Private |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- The Galen, 61 Science Park Road, #06-15, Singapore 117525
- Website
- hummingbirdbioscience.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (2)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
6 January 2026: first patient dosed in the Phase I clinical trial of HMBD-501 in patients with advanced HER3-expressing solid malignancies (company news page, hummingbirdbioscience.com/news).
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Hummingbird Bioscience: engineering precision biotherapeutics (homepage, HQ address and pipeline) · Hummingbird Bioscience
- Hummingbird Bioscience news archive (2025-2026 announcements) · Hummingbird Bioscience
Every entity profile on variis is sourced. Not investment advice.